Okwu mmalite:Nabata na blọgụ MOL Changes.ltd! N'isiokwu a, ọkachamara peptide MD ga-enye gị ntuziaka zuru ezu na otu esi emeghachi ntụ ntụ Tirzepatide, ọgwụ maka ọrịa shuga na ibu ibu[1][5]. Ma ị bụ ọkachamara ahụike, ma ọ bụ onye ọrịa, ịghọta otu esi emeghachi Tirzepatide peptide nke ọma dị oke mkpa iji nweta ihe kacha mma na Tirzepatide..
Kedu ihe bụ Tirzepatide Peptide?
Kedu ihe bụ usoro nke Tirzepatide?
Tirzepatide peptide bụ agonist abụọ nke ndị na-anabata homonụ a maara dị ka GIP (MOL mgbanwe insulinotropic na-adabere na glucose) na GLP-1 (glucagon-dị ka peptide-1). A na-emepụta homonụ ndị a n'ụzọ nkịtị na ahụ ha na-arụkwa ọrụ dị mkpa n'ịhazi ọkwa shuga dị n'ọbara na metabolism.
Na-akpali mmepụta insulin: Tirzepatide na-arụ ọrụ ndị na-anabata GIP na ndị na-anabata GLP-1, Ha abụọ dị na mkpụrụ ndụ beta nke pancreatic, si otú ahụ na-akpali mmepụta insulin. N'ihi ịgbalite ndị nnabata ndị a, pancreas na-ewepụta insulin maka nzaghachi shuga dị n'ọbara. Insulin na-ebelata ọkwa shuga n'ọbara n'ihi na ọ na-enyere sel aka ịmịnye glucose n'ọbara.
Na-egbochi mwepụta nke glucagon: Tirzepatide na-egbochikwa mwepụta nke glucagon, homonụ ọzọ nke pancreas mepụtara. Glucagon na-ebuli shuga dị n'ọbara site n'ime ka imeju hapụ glucose echekwara. Tirzepatide na-akwụsị mmepụta glucose karịrị akarị site na ibelata ntọhapụ nke glucagon.
Ịchịkwa agụụ agụụ na mkpofu afọ: N'akụkụ ụbụrụ na-etinye aka na nchịkwa agụụ, Ndị na-anabata GLP-1 dịkwa. Tirzepatide na-akwalite satiety ma belata oriri nri site na ịgbalite ndị na-anabata ya. Na mgbakwunye, GLP-1 na-achịkwa ọnụego nke nri, gụnyere glucose, na-etinye obi gị dum n'ọbara mgbe ị risịrị nri site na ibelata mkpofu gastric.
Mbelata ibu: Ihe omume agonist dual agonist nke Tirzepatide na GIP na ndị na-anabata GLP-1 jikọtara ya na oke ibu dị arọ.. Site n'ịhazi ojiji abụba na ịba ụba satiety, ọ nwere ike inye aka belata oriri calorie yana ịbawanye mmefu ume.
Tirzepatide na-arụ ọrụ site na ịgbalite GIP na GLP-1 nnabata iji dozie okwu dị iche iche,gụnyere ụkpụrụ shuga ọbara, mmepụta insulin, mbelata glucagon, na ịchịkwa agụụ.
Otu esi eme Rihe mejupụtara nke Tirzepatide Ntụ ntụ?
A na-ekewa nwughari nke Tirzepatide ntụ ntụ nzọụkwụ isii.
Nzọụkwụ 1 Chọta nke rgburugburu ebe obibi
Chọta ebe dị ọcha na nke ọma iji dozie ọgwụ ahụ mgbe ị na-emegharị ntụ ntụ Tirzepatide. Gbaa mbọ hụ na elu enweghị mmetọ ọ bụla. MOL Mgbanwe
Nzọụkwụ 2 Kwadebe ndị mkpa item
Tirzepatide ntụ ntụ
Mmiri na-adịghị mma maka ntụtụ
Vial nkwụnye
sirinji
Nzọụkwụ 3 Wntụ aka gị
Jiri ncha na mmiri na-asa aka gị nke ọma tupu ịmaliteghachi ntụ ntụ Tirzepatide iji gbochie iwebata nje bacteria ma ọ bụ ihe ndị ọzọ na-emerụ ahụ.
Nzọụkwụ 4 Tinyegharịa Tirzepatide pokwa
① Lelee vial Tirzepatide peptide maka akara ọ bụla nke mmebi ma ọ bụ mmetọ. Ejila ma ọ bụrụ na agbajiri vial ma ọ bụ ntụ ntụ agbanweela agba;
②Wepu okpu nchebe na vial nwere ntụ ntụ Tirzepatide;
③ Jiri mmiri mmanya na-egbu egbu hichapụ ihe mgbochi rọba na vial;
④ Jikọọ ihe nkwụnye ọkụ na vial;
⑤ Dị ka ntuziaka si dị, bulie sirinji ma see oke mmiri na-adịghị mma maka ịgba ọgwụ;
⑥ Jiri nwayọọ gbanye mmiri na-adịghị ọcha n'ime vial nke Tirzepatide peptide. Tụgharịa iyi mmiri n'akụkụ akụkụ nke vial ahụ ka ibelata ụfụfụ.
⑦ Jiri nwayọọ tụgharịa vial ka ị gwakọta mmiri na ntụ ntụ, emela jijiji nke ukwuu;
⑧ Lelee ngwọta edozigharị maka ihe ọ bụla ma ọ bụ clumps, jide n'aka na agbazewo ntụ ntụ kpamkpam tupu ọ gaa n'ihu. Ọ bụrụ na achọpụtara nsogbu ọ bụla, ejila ihe ngwọta a ma tụfuo ya nke ọma.
Nzọụkwụ 5 Wepụ ihe ngwọta Tirzepatide agwakọta
①Tụgharịa vial ma tinye sirinji n'ime ihe nkwụnye vial;
② Jiri nwayọ weghachi onye na-ebu ihe iji wepụta ọgwụ Tirzeparatide achọrọ;
③ Lelee sirinji maka afụ ikuku, ọ bụrụ na ọ dị, kpatụ sirinji ahụ ntakịrị ka ịchụpụ ya.
Nzọụkwụ 6 nchịkwa
Mgbe ị wepụrụ ihe ngwọta Tirzepatide, gbanye n'ebe a na-agba ntụtụ dị ka a gwara ya.
Kedu uru nke Tirzepatide peptide??
- Kwalite ibu ibu[3][6]. Site n'igbochi agụụ, satiety na-abawanye, ibelata oriri calorie, ka iji nweta ibu ọnwụ.
- Jikwaa ma mee ka ọ̀tụ̀tụ̀ shuga dị n'ọbara kwụsie ike[2][4]. Tirzepatide nwere ike ijikwa ma mee ka ọ̀tụ̀tụ̀ shuga dị n'ọbara kwụsie ike site n'ịhazi GLP-1 na GIP (iji belata haemoglobin glycated (HbA1c) ọkwa.
- Ọgwụgwọ ọrịa ndị metụtara oke ibu. Tirzepatide nwere ike belata ọrịa ndị metụtara oke ibu (elu atọ) ma chebe usoro obi obi.
- Dị mma. Tirzepatide kwesịrị ịgbanye naanị otu ugboro n'izu, nke na-eme ka ndụ ndị ọrịa dịkwuo mfe.
- Usoro nchịkwa na-agbanwe agbanwe. Enwere ike iji Tirzepatide naanị ya ma ọ bụ ọgwụ shuga ndị ọzọ iji rụọ ọrụ nke ọma.
Mmetụta ọnwụ siri ike na-eme ka Tirzepatide kwadoro site na nkwenye ndị ọkachamara
Ndị ọkachamara kwenyere na oke ibu—karịsịa oke ibu afọ — bụ ihe nwere ike ibute ASCVD.. Mbelata ibu abụghị naanị njikwa ibu, mana gbasara imeziwanye ọtụtụ ihe ize ndụ ASCVD iji belata ọrịa ASCVD na ọnwụ. A na-ekewa ọgwụ antidiabetic ugbu a n'ime 4 klaasị dabere na mmetụta ọnwụ ha dị arọ: ike dị ukwuu, ike, agafeghị oke na enweghị mmetụta. Ndị ọkachamara kwenyere na Tirzepatide na Semaglutide bụ ndị ọrụ hypoglycemic kachasị dị irè maka ịbelata ibu.. N'ezie, usoro ọmụmụ SURPASS na Tirzepatide egosila mmetụta dị ukwuu na ọnwụ dị arọ.
Otu dose atọ nke Tirzepatide lyophilized ntụ ntụ (5 mg, 10 mg, 15 mg) gosiri mmetụta ọnwụ dị arọ karịa otu njikwa niile (gụnyere placebo ma ọ bụ ọgwụ nchịkwa na-arụ ọrụ) na usoro ọmụmụ SURPASS, na ibu ibu sitere na 6.5% ka 13.9%. Ọmụmụ ihe a na-egosi na ndị ọrịa nwere T2DM nwere ike iji ọgwụ ndị dị irè karị maka ọnwụ ụlọ ọgwụ. Ọgwụ ndị a dị irè n'ibelata ihe ize ndụ ASCVD. Na mgbakwunye, na SURPASS-AP-Combo ọmụmụ nso nso a metụtara ndị okenye China nwere ọrịa shuga T2, atọ dose dị iche iche nke Tirzepatide gosikwara nnukwu ọnwụ mmetụta (Tirzepatide belatara site na 6.5% ka 9.4%; otu njikwa mụbara site 2.1%) , P < 0.05), nke na-enye ihe akaebe ahụike na-egosi maka ojiji n'ọdịnihu. Nkwekọrịta ndị ọkachamara kwenyere na ASCVD nwere njikọ chiri anya na ọtụtụ ihe ngosi metabolic (ọbara mgbali elu, lipids ọbara, ọbara shuga, wdg.), ewezuga njikwa ibu.
Nkwekọrịta ndị ọkachamara na-atụ aro ka ndị ọrịa na-abụghị ndị ime ime dobe HbA1c n'okpuru 7.0% iji belata ihe ize ndụ nke ASCVD. Ọ bụ ihe gbasara ibu ibu. N'usoro ọmụmụ SURPASS, Otu atọ ọgwụ Tirzepatide gosipụtara mmetụta hypoglycemic dị ukwuu (iru eru nke 75% ka 97%, HbA1c nke 7.0%).
MOL na-agbanwe ọgwụ na-efunahụ arọ Vs ọgwụ na-ebelata ibu omenaala
MOL omenala na-agbanwe arụmọrụ
Ụfọdụ ngwaahịa na-ebelata ibu nke ọdịnala na-enwe mmetụta dị nta na mbelata ibu (dị ka Rimonaban);
Ụfọdụ ịkwụsị iji ha eme ihe ga-eduga n'ịghaghachi ibu(dị ka sibutramine).
Mmetụta dị ịrịba ama, na mmetụta ọnwụ ya nwere ike na-erukarị 10%-20%;
A gaghị enwe isi nkwụghachi ibu mgbe ị kwụsịrị iji ya.
Mmetụta nwere ike ibute nsonaazụ dịka ọrịa kansa, ọrịa obi, na mmebi akwara ozi.Dịka ọgwụ nje, nwere mmetụta dị nta dị nta. Ụzọ nchịkwa a na-aṅụ ọnụ ma na-aṅụ kwa ụbọchị. Site na injections na ọtụtụ bụ otu ugboro n'izu.[7]
Otu esi echekwa ntụ ntụ lyophilized Tirzepatide?
Ụdị ntụ ntụ Lyophilized Tirzepatide kwesịrị ịchekwa na friji (n'etiti 2-8ºC). Debe tirzepatide na ngwugwu mbụ ruo mgbe ejiri ya kpuchie ọkụ. Mpekere otu dose (Mmiri mmiri ọgwụ Tirzepatide) nwere ike ịchekwa na ụlọ okpomọkụ maka 21 ụbọchị, ọ bụrụ na ọ dị mkpa. Ejila Tirzepatide ifriizi. Ntu oyi nwere ike imebi ọgwụ ahụ ma metụta ịdị irè ya. Chekwaa ọgwụ gị naanị dị ka onye na-ebubata Tirzepatide gwara gị dị ka MOL Changes.ltd. Jide n'aka na ị ghọtara ka esi echekwa peptide gị nke ọma.
Tirzepatide ntụ ntụ usoro onunu ogwu - Otu esi eji Tirzepatide?
MOL Changes.ltd dị ka onye na-eweta Tirzepatide. Anyị na-eme nke ọma n'ịmepụta ntụ ntụ Tirzepatide dị elu. The Tirzepatide powder dosage na ozi nchịkwa enyere ebe a bụ maka ebumnuche ozi naanị na e kwesịghị iwere ya dị ka ndụmọdụ ahụike.. Ngwunye nke tirzepatide lyophilized ntụ ntụ nwere ike ịdịgasị iche dabere na ebumnuche ya maka ụdị 2 ọrịa shuga na ibu ibu. Dabere na ọtụtụ ọmụmụ, ebe a bụ ntuziaka usoro ọgwụgwọ tirzepatide izugbe:
Usoro ọgwụgwọ Tirzepatide maka Ụdị 2 Ọrịa shuga mellitus
Tirzepatide(Mounjaro) A na-eji peptide dị ka ihe mgbakwunye nri na mmega ahụ iji melite njikwa glycemic na ndị okenye nwere ụdị 2 ọrịa shuga mellitus. Usoro onunu ogwu na-agbaso usoro a:
Usoro izizi: 2.5 mg injection subcutaneous otu ugboro n'izu maka 4 izu.
Usoro nlekọta: Na-abawanye na 5 mg injection subcutaneous otu ugboro n'izu mgbe mmalite 4 izu.
Titration: Ọ bụrụ na achọrọ njikwa glycemic ọzọ, Enwere ike ịbawanye dose ahụ n'ime 2.5 mg abawanye ma ọ dịkarịa ala 4 izu na dose ugbu a.
Oke dose: Oke kachasị akwadoro bụ 15 mg injection subcutaneous otu ugboro n'izu.
Biko mara na nke mbụ 2.5 dose mg bụ maka mmalite ọgwụgwọ na ọ naghị arụ ọrụ maka njikwa glycemic. Ị ga-achọ ịgbanwe usoro onunu ogwu gị dabere na nzaghachi gị na mkpa gị.
Usoro Tirzepatide maka mbelata ibu
E gosiputara peptide tirzepatide iji nyere aka felata ibu na ndị ọrịa buru oke ibu. Usoro ọgwụgwọ maka ịbelata ibu nwere ike ịdị iche ma enwere ike ịgwa ya site na nnwale ụlọ ọgwụ dịka SURMOUNT-1 na SURMOUNT-2.. MOL Changes.ltd as Tizepatide powder manufacturer don’t teach how to use Tirzepatide. But a potential weight loss protocol could be:
Usoro izizi: 2.5 mg subcutaneous injection once a week for the first four weeks.
Progressive Increase: Increase the dose to 5 mg weekly in weeks 5-8, 7.5 mg weekly in weeks 9-12, na 10 mg weekly in weeks 13-16.
Further Adjustment: Depending on individual response and tolerance, consider increasing to 12.5 mg weekly in weeks 17-20, and up to a maximum dose of 15 mg weekly from week 21 onwards.
Frequency and Duration: Administer once-weekly subcutaneous injections, and studies using this protocol have lasted 24-72 izu.
It’s essential to consult your healthcare provider before making any changes to your medication dosage. This guide is a general overview and should not replace personalized medical advice. Onye na-ahụ maka ahụike gị ga-ekpebi usoro ọgwụgwọ kwesịrị ekwesị maka ọnọdụ gị na mkpa gị. MOL Changes.ltd
Ajụjụ A na-ajụkarị (FAQ) FAQ
1.Q: Kedu ka esi echekwa ihe ngwọta Tirzepatide ntụ ntụ emegharịrị?
A: Mgbe mweghachi, Ekwesịrị ịchekwa ngwọta Tirzepatide na friji na 36°F ruo 46°F (2Celsius C ruo 8 Celsius). Adịla ifriizi ihe ngwọta. Ekwesịrị iji ngwọta emegharịrị emezigharị n'ime 8 awa
2.Q: Enwere ike ịgwakọta ntụ ntụ lyophilized Tirzepatide na ọgwụ ndị ọzọ?
A: Mba, E kwesịghị ịgwakọta Tirzepatide na ọgwụ ọ bụla ọzọ n'otu sirinji. Ekwesịrị inye ha iche iche iji zere esemokwu ọgwụ.
3.Q: Gịnị ma ọ bụrụ na m na-atụ uche a dose Tirzepatide peptide?
A: Ọ bụrụ na ị na-atụ uche dose nke Tirzepatide were ọgwụ agbagharaghị ozugbo ị chetara ya, ọ bụrụ n'ime 4 ụbọchị mgbe dose ahụ furu efu. Agbanyeghị, ọ bụrụ na ọ kariri 4 ụbọchị site na ọgwụ ikpeazụ gị wee gaa n'ihu dose ahụ furu efu wee gaa n'ihu n'usoro usoro onunu ogwu gị. Agbala ọgwụ abụọ n'ime 3 ụbọchị nke ọ bụla ọzọ.
4.Q: Enwere mmetụta ọ bụla nke Tirzepatide?
A: Dị ka ọ dị na ọgwụ ọ bụla, Tirzepatid nwere ike ibute nsonaazụ. Mmetụta ndị na-emekarị gụnyere ọgbụgbọ, vomiting, afọ ọsịsa, na mmeghachi omume saịtị injection. Mgbanwe na akụrụ gị (dị ka mgbanwe na oke mmamịrị), ọhụụ (dị ka mbelata/nhụsịrị anya), pancreas, ma ọ bụ ọrịa gallbladder (dị ka ọgbụgbọ / vomiting na-adịgide adịgide, oke mgbu afọ/afọ) bụ mmetụta dị njọ nke chọrọ nlekọta ahụike ozugbo.
5.Q: Enwere ike ịgwakọta ntụ ntụ Tirzepatide tupu oge eruo?
A: Mba, a na-atụ aro ka ị gwakọta ntụ ntụ Tirzepatide ozugbo tupu ejiri ya mee ihe iji hụ na ike ya dị.
6.Q: Kedu ihe m ga-eme ma ọ bụrụ na m maa jijiji vial na mberede?
A: Ọ bụrụ na ị na-ama jijiji vial na mberede, hapụ ya ka ọ nọdụ ala nkeji ole na ole ka ikuku ikuku na-edozi. Ejila ma ọ bụrụ na ngwọta na-afụ ụfụfụ ma ọ bụ nwere ihe ndị a na-ahụ anya.
7.Q: Enwere ike ijikwa ihe nkwụnye vial ahụ ọzọ?
A: Mba, ihe nkwụnye vial bụ maka naanị otu ojiji. Tụfuo ya nke ọma mgbe ejiri ya ọ bụla.
8.Q: Kedu ka esi enye Tirzepatide n'ụzọ ziri ezi?
A: A na-atụ aro ka ị were otu ugboro n'izu dịka ntuziaka ahụ si dị. Enwere ike were ya na nri ma ọ bụ na afọ efu. Enwere ike ịgbanye ya n'apata ụkwụ, afo ma ọ bụ elu ogwe aka. Ekwesịrị ịtụgharị saịtị ịgba ntụtụ oge ọ bụla.
Isi ihe iji mara
Tirzepatide bụ MOL mgbanwe eji agwọ ụdị 2 ọrịa shuga na oke ibu.
Nhazigharị Tirzepatide nke ọma dị oke mkpa maka ịrụ ọrụ ya.
Soro ntuziaka nzọụkwụ-site-nzọụkwụ enyere iji megharia
Chekwaa ngwọta a kwadebere na refrjiraeto ma jiri n'ime 8 awa.
Ejikọtala Tirzepatide na ọgwụ ndị ọzọ n'otu sirinji.
Otu esi azụta ntụ ntụ Tirzepatide?
Ọ ga-amasị gị ịzụta Tirzepatide Peptides kacha mma n'aka ndị na-eweta Tirzepatide ntụ ntụ kacha mma n'ahịa.? Ị bịarutere ebe kwesịrị ekwesị!
MOL Changes.ltd dị ka ụlọ ọrụ peptide bụ ebe kacha mma maka ịzụta peptide Tirzepatide na ọnụ ahịa asọmpi site na obere ruo nnukwu..
Nchịkọta
Tirzepatide dị irè na ọgwụgwọ ụdị 2 ọrịa shuga na oke ibu, na ịmụta otú e si ejikọta Tirzepatide ntụ ntụ bụ ihe dị mkpa iji jikwaa ahụike gị nke ọma. Site n'ịgbaso usoro nrụzigharị enyere n'ime edemede a kpọtụrụ aha, ị nwere ike ịkwadebe nke ọma ma were ọgwụ a.
Maka ozi ndị ọzọ:Tirzepatide
Onye dere edemede a:
Dr. Jean Zeng gụsịrị akwụkwọ na King's college london ngalaba nke Life Sciences & Ọgwụ.
Akwụkwọ akụkọ Sayensị Odee:
Mahadum Lorraine, CHRU de Nancy, Ụlọ ọgwụ ndị okenye Brabois, ngalaba endocrinology, ọrịa shuga mellitus na nri, rue du Morvan, 54500 Vandoeuvre-lès-Nancy, France
Ụlọ ọrụ nyocha nke ọrịa shuga UAB, Mahadum Alabama na Birmingham, Birmingham, AL, USA
3,Qi Liu
Ụlọ ọrụ nyocha nke obi na Mahadum Wuhan, Wuhan 430060, Hubei, PR China
Ngalaba Ọgwụ, Ụlọ Akwụkwọ Ọgwụ nke Mahadum Koc, Istanbul 34010, toro toro
5,Francine Mendoza B.S., Pharm.D. Onye ndoro-ndoro ochichi
Harold Schnitzer Center Health maka Ọrịa shuga (HSDHC), Oregon Health and Science University (OHSU), 3270 SW Pavilion Loop, Portland, MA ọ bụ 97239
N'ụzọ ọ bụla dọkịta / ọkà mmụta sayensị anaghị akwado ma ọ bụ kwado ịzụrụ ya, ire ere, ma ọ bụ iji ngwaahịa a maka ihe ọ bụla. MOL Changes.ltd enweghị njikọ ma ọ bụ mmekọrịta, pụtara ma ọ bụ ọzọ, ya na dibia bekee. Ebumnuche nke ịkpọ dọkịta a bụ ịnakwere, kwenye na ịja mma nyocha na ọrụ mmepe nke ndị ọkà mmụta sayensị na-arụ ọrụ na peptide a na-agwụ ike.
Ntụtu aka
[1]FDA kwadoro akwụkwọ akụkọ, Ọgwụgwọ Ezubere Abụọ maka Ụdị 2 Ọrịa shuga mellitus
[2]Ọrụ Tirzepatide, Dual GIP na GLP-1 Nnabata Agonist, na Management nke Ụdị 2 Ọrịa shuga mellitus: Ọnwụnwa ụlọ ọgwụ SURPASS
[3]”Tirzepatide belatara nke ukwuu A1C na ịdị arọ ahụ na ndị nwere ụdị 2 ọrịa shuga mellitus n'ụdị abụọ 3 ule sitere na mmemme SURPASS nke Lilly” (mbipụta ndị nchụ nta akụkọ). Eli Lilly na ụlọ ọrụ. 17 Febụwarị 2021. Edebere ya na nke mbụ 28 October 2021. eweghachiri 28 October 2021 - site na PR Newswire
[4]Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, et al. (Jenụwarị 2021). "Dual GIP na GLP-1 Onye na-anabata Agonist Tirzepatide na-eme ka arụ ọrụ beta-cell na mmetụta insulin n'ụdị. 2 Ọrịa shuga mellitus". Akwụkwọ akụkọ nke Clinical Endocrinology na Metabolism. 106 (2): 388-396. doi:10.1210/mkpọda/dgaa863. PMC 7823251. PMID 33236115.
[5]Dahl D, Onishi Y, Norwood P, ehh R, Bray R, Patel H, Rodríguez Á (Febụwarị 2022). "Mmetụta nke Subcutaneous Tirzepatide vs Placebo Agbakwunyere na Insulin Glargine Titrated na njikwa glycemic na ndị ọrịa nwere ụdị. 2 Ọrịa shuga mellitus: Ọnwụnwa ụlọọgwụ nke SURPASS-5 Randomized". JAMA. 327 (6): 534-545. doi:10.1001/Jama.2022.0078. PMC 8826179. PMID 35133415.
[6]”Lilly : Usoro 3 Nsonaazụ Tirzepatide na-egosi A1C dị elu yana mbelata ibu ahụ n'ụdị 2 Ọrịa shuga mellituss". Business Insider. Akụkọ RTTT. 19 October 2021. Edebere ya na nke mbụ 28 October 2021. eweghachiri 28 October 2021.
[7]Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Kọnịri L, Alves B, et al. (4 June 2022). "Tirzepatide Otu ugboro kwa izu maka ọgwụgwọ oke ibu". NEJM. 387 (3): 205-216. doi:10.1056/NEJMoa2206038. PMID 35658024. S2CID 249385412. Edebere ya na nke mbụ 5 June 2022. eweghachiri 6 June 2022.
Nkwuputa: Ọdịnaya dị n'ime akụkọ a bụ naanị maka ebumnuche ozi izugbe. O nwere ike ghara ịbụ eziokwu, zuru oke na e kwesịghị iwere ya dịka ahụike, iwu, ndụmọdụ ego ma ọ bụ ndụmọdụ ọkachamara ndị ọzọ. Omume ma ọ bụ mkpebi ọ bụla emere dabere na ozi a bụ naanị ọrụ dịịrị onye ọrụ
